

Special Issue

State of the Art and Novelties in Multidisciplinary Approach to Soft Tissue and Bone Sarcomas

Message from the Guest Editors

There is no current literature consensus regarding the optimal diagnostic and treatment approach to soft tissue sarcomas (STSs). Recent publications highlighted new biological aspects and deeper genetic characterization of different types of STS, up-to-date research works focused on a highly personalized medicine approach to the treatment of STS, and modern imaging techniques (e.g. PET-MRI). In the past decade, the use of neoadjuvant and adjuvant chemotherapy, new developed immunotherapies, combined Hyperthermia with chemo-irradiation, and advances in radiation therapy techniques, like Stereotactic Body Radiation Therapy (SBRT) or the use of Artificial Intelligence to detect radio-sensitive areas of the STS, were studied but conclusive results are still debated.

The aim of the Special issue is to provide readers with a full comprehensive data collection on up-to-date studies and treatments for defining shared guidelines and obtaining a consensus in approaches to STS. The following types of submissions will be considered: original studies, meta-analysis and systematic reviews, clinical trial studies.

Guest Editors

Dr. Ron Batash

Dr. Alberto Crimi

Prof. Dr. Moshe Schaffer

Prof. Dr. Pietro Ruggieri

Deadline for manuscript submissions

closed (28 February 2026)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/210796

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)